Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis

Littlewood KJ, Greiner W, Baum D, Zoellner Y (2007)
BMC Nephrology 8(1): 9.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA
Autor*in
Littlewood, Kavi J.; Greiner, WolfgangUniBi; Baum, Dominique; Zoellner, York
Abstract / Bemerkung
Background: Systemic hypertension often accompanies chronic renal failure and can accelerate its progression to endstage renal disease (ESRD). Adjunctive moxonidine appeared to have benefits versus adjunctive nitrendipine, in a randomised double-blind six-month trial in hypertensive patients with advanced renal failure. To understand the longer term effects and costs of moxonidine, a decision analytic model was developed and a cost-effectiveness analysis performed. Methods: A Markov model was used to extrapolate results from the trial over three years. All patients started in a non- ESRD state. After each cycle, patients with a glomerular filtration rate below 15 ml/min had progressed to an ESRD state. The cost-effectiveness analysis was based on the Dutch healthcare perspective. The main outcome measure was incremental cost per life-year gained. The percentage of patients progressing to ESRD and cumulative costs were also compared after three years. In the base case analysis, all patients with ESRD received dialysis. Results: The model predicted that after three years, 38.9% (95%CI 31.8–45.8) of patients treated with nitrendipine progressed to ESRD compared to 7.5% (95%CI 3.5–12.7) of patients treated with moxonidine. Treatment with standard antihypertensive therapy and adjunctive moxonidine was predicted to reduce the number of ESRD cases by 81% over three years compared to adjunctive nitrendipine. The cumulative costs per patient were significantly lower in the moxonidine group €9,858 (95% CI 5,501–16,174) than in the nitrendipine group €37,472 (95% CI 27,957–49,478). The model showed moxonidine to be dominant compared to nitrendipine, increasing life-years lived by 0.044 (95%CI 0.020–0.070) years and at a cost-saving of €27,615 (95%CI 16,894–39,583) per patient. Probabilistic analyses confirmed that the moxonidine strategy was dominant over nitrendipine in over 98.9% of cases. The cumulative 3-year costs and LYL continued to favour the moxonidine strategy in all sensitivity analyses performed. Conclusion: Treatment with standard antihypertensive therapy and adjunctive moxonidine in hypertensive patients with advanced renal failure was predicted to reduce the number of new ESRD cases over three years compared to adjunctive nitrendipine. The model showed that adjunctive moxonidine could increase life-years lived and provide long term cost savings.
Erscheinungsjahr
2007
Zeitschriftentitel
BMC Nephrology
Band
8
Ausgabe
1
Art.-Nr.
9
ISSN
1471-2369
Page URI
https://pub.uni-bielefeld.de/record/2477687

Zitieren

Littlewood KJ, Greiner W, Baum D, Zoellner Y. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology. 2007;8(1): 9.
Littlewood, K. J., Greiner, W., Baum, D., & Zoellner, Y. (2007). Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology, 8(1), 9. doi:10.1186/1471-2369-8-9
Littlewood, K. J., Greiner, W., Baum, D., and Zoellner, Y. (2007). Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology 8:9.
Littlewood, K.J., et al., 2007. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology, 8(1): 9.
K.J. Littlewood, et al., “Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis”, BMC Nephrology, vol. 8, 2007, : 9.
Littlewood, K.J., Greiner, W., Baum, D., Zoellner, Y.: Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis. BMC Nephrology. 8, : 9 (2007).
Littlewood, Kavi J., Greiner, Wolfgang, Baum, Dominique, and Zoellner, York. “Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis”. BMC Nephrology 8.1 (2007): 9.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
Dieses Objekt ist durch das Urheberrecht und/oder verwandte Schutzrechte geschützt. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:00Z
MD5 Prüfsumme
60d3e458a43d8eed2c01644cafb6e0e7

2 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy.
Menzin J, Lines LM, Weiner DE, Neumann PJ, Nichols C, Rodriguez L, Agodoa I, Mayne T., Pharmacoeconomics 29(10), 2011
PMID: 21671688

30 References

Daten bereitgestellt von Europe PubMed Central.

De maatschappelijke kosten van nierziekten in Nederland
De GA, Polder JJ, Jager KJ, De FTh., 2001
Blood pressure and end-stage renal disease in men.
Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J., N. Engl. J. Med. 334(1), 1996
PMID: 7494564
Progression of chronic renal failure.
Yu HT., Arch. Intern. Med. 163(12), 2003
PMID: 12824091
Audit of antihypertensive treatment in patients with renal failure.
Schwenger V, Ritz E., Nephrol. Dial. Transplant. 13(12), 1998
PMID: 9870471
The role of sympathetic nervous activity in chronic renal failure
Rump LC., 2001
Renal Parenchymal Hypertension: current concepts of pathogenesis and management.
Preston RA, Singer I, Epstein M., Arch. Intern. Med. 156(6), 1996
PMID: 8629871
Sympathetic overactivity in patients with chronic renal failure.
Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG., N. Engl. J. Med. 327(27), 1992
PMID: 1454086
Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure.
Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ., J. Am. Soc. Nephrol. 15(11), 2004
PMID: 15504943
Moxonidine treatment of hypertensive patients with advanced renal failure.
Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC., J. Hypertens. 21(9), 2003
PMID: 12923404
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G., Lancet 354(9176), 1999
PMID: 10437863
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group., N. Engl. J. Med. 345(12), 2001
PMID: 11565517
Interleukin-12 alters the physicochemical characteristics of serum and glomerular IgA and modifies glycosylation in a ddY mouse strain having high IgA levels.
Kobayashi I, Nogaki F, Kusano H, Ono T, Miyawaki S, Yoshida H, Muso E., Nephrol. Dial. Transplant. 17(12), 2002
PMID: 12454220
US National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF/DOQI)
AUTHOR UNKNOWN, 0
Section I. Measurement of renal function, when to refer and when to start dialysis.
European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association., Nephrol. Dial. Transplant. 17 Suppl 7(), 2002
PMID: 12386205

Fernández-Abascal H, Guijarro MM, Rojo JL, Sanz JA., 1994
Distributions in Statistics
Johnson NL., 0
ERA EDTA Annual report
AUTHOR UNKNOWN, 2002
Economic evaluation of benazepril in chronic renal insufficiency.
van Hout BA, Simeon GP, McDonnell J, Mann JF., Kidney Int. Suppl. 63(), 1997
PMID: 9407447
Economic evaluation of end stage renal disease treatment.
de Wit GA, Ramsteijn PG, de Charro FT., Health Policy 44(3), 1998
PMID: 10182294
OECD
AUTHOR UNKNOWN, 0
. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg
Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH., 2004
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G., N. Engl. J. Med. 330(13), 1994
PMID: 8114857
The renoprotective effect of combined antihypertensive drugs.
Del Vecchio L, Locatelli F., J. Nephrol. 14(1), 2001
PMID: 11281347
Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies?
Locatelli F, Del Vecchio L, D'Amico M, Andrulli S., J. Am. Soc. Nephrol. 13 Suppl 3(), 2002
PMID: 12466314
The cost-effectiveness of early surgery versus watchful waiting in the management of small abdominal aortic aneurysms
Katz DA, Cronenwett JL., 1994
The renal arterial resistance index and renal allograft survival.
Radermacher J, Mengel M, Ellis S, Stuht S, Hiss M, Schwarz A, Eisenberger U, Burg M, Luft FC, Gwinner W, Haller H., N. Engl. J. Med. 349(2), 2003
PMID: 12853584

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Quellen

PMID: 17645811
PubMed | Europe PMC

Suchen in

Google Scholar